Chitosan microspheres enhance the immunogenicity of an Ag85B-based fusion protein containing multiple T-cell epitopes of Mycobacterium tuberculosis

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 66, Issue 3, 2007, Pages 318-326

  Zhu, Bing dong ^a,b   Qie, Ya qing ^a   Wang, Jiu ling ^a   Zhang, Ying ^a,c   Wang, Qing zhong ^a   Xu, Ying ^a   Wang, Hong hai ^a  

^a FUDAN UNIVERSITY   (China)

^b LANZHOU UNIVERSITY   (China)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Adjuvant; Chitosan microspheres; Fusion protein; Mycobacterium tuberculosis; Subunit vaccine

Indexed keywords

ANTIGEN; CARRIER PROTEIN; CHITOSAN; EPITOPE; FREUND ADJUVANT; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; MICROSPHERE; PHOSPHATE BUFFERED SALINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIODEGRADABILITY; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; GENE; GENETIC CODE; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOSTIMULATION; IN VITRO GENE TRANSFER; MORPHOLOGY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PARTICLE SIZE; PRODUCTIVITY; SPLEEN CELL; TUBERCULOSIS; ZETA POTENTIAL;

ACYLTRANSFERASES; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BASE SEQUENCE; CHITOSAN; CYTOKINES; EPITOPES, T-LYMPHOCYTE; FEMALE; INTERFERON TYPE II; MICE; MICE, INBRED C57BL; MICROSPHERES; MOLECULAR SEQUENCE DATA; MYCOBACTERIUM TUBERCULOSIS; RECOMBINANT FUSION PROTEINS; TUBERCULOSIS VACCINES; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 34247583819     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2006.11.028     Document Type: Article

References (33)

1. Onyebujoh P., and Rook G.A.W. Tuberculosis. Nat. Rev. Microbiol. 2 (2004) 930-932
2. Fine P.E. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346 (1995) 1339-1345
3. Andersen P., and Doherty T.M. The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat. Rev. Microbiol. 3 (2005) 656-662
4. Okkels L.M., Doherty T.M., and Andersen P. Selecting the components for a safe and efficient tuberculosis subunit vaccine - recent progress and post-genomic insights. Curr. Pharm. Biotechnol. 4 (2003) 69-83
5. 37Ra. Vaccine 15 (1997) 689-699
6. Lozes E., Huygen K., Content J., Denis O., Montgomery D.L., Yawman A.M., Vandenbussche P., Vooren J.P.V., Drowart A., Ulmer J.B., and Liu M.A. Immunogenicity and efficacy of a tuberculosis DNA vaccine encoding the components of the secreted antigen 85 complex. Vaccine 15 (1997) 830-833
7. Coler R.N., Campos-Neto A., Ovendale P., Day F.H., Fling S.P., Zhu L.Q., Serbina N., Flynn J.A.L., Reed S.G., and Alderson M.R. Vaccination with the T cell antigen Mtb 8.4 protects against challenge with Mycobacterium tuberculosis. J. Immunol. 166 (2001) 6227-6235
8. + T cells with specificity for a novel mycobacterial epitope. Int. Immunol. 13 (2001) 451-458
9. Kaufmann S.H.E. How can immunology contribute to the control of tuberculosis?. Nat. Rev. Immunol. 1 (2001) 20-30
10. Glatman-Freedman A. Advances in antibody-mediated immunity against Mycobacterium tuberculosis: implications for a novel vaccine strategy. FEMS Immunol. Med. Microbiol. 39 (2003) 9-16
11. Lindblad E.B., Elhay M.J., Silva R., Appleberg R., and Andersen P. Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Infect. Immun. 65 2 (1997) 623-629
12. Lima K.M., Santos S.A., Rodrigues J.M., and Silva C.L. Vaccine adjuvant: it makes the difference. Vaccine 22 (2004) 2374-2379
13. + T-cell-mediated immune response against Mycobacterium tuberculosis antigen Mtb8.4. Vaccine 22 (2004) 1964-1972
14. Wilkinson K.A., Belisle J.T., Mincek M., Wilkinson R.J., and Toossi Z. Enhancement of the human T cell response to culture filtrate fractions of Mycobacterium tuberculosis by microspheres. J. Immunol. Methods 235 (2000) 1-9
15. Carpenter Z., Williamson E.D., and Eyles J.E. Mucosal delivery of microparticle encapsulated ESAT-6 induces robust cell-mediated responses in the lung milieu. J. Control. Release 104 (2005) 67-77
16. van der Lubben I.M., Verhoef J.C., Borchard G., and Junginger H.E. Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur. J. Pharm. Sci. 14 (2001) 201-207
17. Illum L., Jabbal-Gill I., Hinchcliffe M., Fisher A.N., and Davis S.S. Chitosan as a novel nasal delivery system for vaccines. Adv. Drug Deliv. Rev. 51 (2001) 81-96
18. Vila A., Sanchez A., Janes K., Behrens I., Kissel T., Vila Jato J.L., and Alonso M.J. Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur. J. Pharm. Biopharm. 57 (2004) 123-131
19. Lubben L.M., Kersten G., Fretz M.M., Beuvery C., Verhoef J.C., and Junginger H.E. Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice. Vaccine 21 (2003) 1400-1408
20. Seferian P.G., and Martinez M.L. Immune stimulating of two new chitosan containing adjuvant formulations. Vaccine 19 (2001) 661-668
21. Nishimura K., Nishimura S., Nishi N., Numata F., Tone Y., Tokura S., and Azuma I. Adjuvant activity of chitin derivatives in mice and guinea-pigs. Vaccine 3 (1985) 379-384
22. Shibata Y., Foster L.A., Metzger W.J., and Myrvik Q.N. Alveolar macrophage priming by intravenous administration of chitin particles polymers of N-acetyl-d-glucosamine in mice. Infect. Immun. 65 (1997) 1734-1741
23. Bivas-Benita M., Meijgaarden K.E., Frenken K.L., Junginger H.E., Borchard G., Ottenhoff T.H.M., and Geluk A. Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A *0201-restricted T-cell epitopes of Mycobacterium tuberculosis. Vaccine 22 (2004) 1609-1615
24. Zhi G., Wang B.L., Ji C.N., Zhu Q.Q., and Wang H.H. The expression and purification of Ag85B of Mycobacterium Tuberculosis (in Chinese). J. Fudan University (Nat. Sci.) 41 (2002) 113-116
25. Jaganathan K.S., Rao Y.U.B., Singh P., Prabakaran D., Gupta S., Jain A., and Vyas S.P. Development of a single dose tetanus toxoid formulation based on polymeric microspheres: a comparative study of poly (d,l-lactic-co-glycolic acid) versus chitosan microspheres. Int. J. Pharm. 294 (2005) 23-32
26. Tabata I., and Ikada Y. Phagocytosis of polymer microspheres by macrophages. Adv. Polym. Sci. 94 (1990) 107-141
27. Aiba S. Studies on chitosan: 4. Lysozymic hydrolysis of partially N-acetylated chitosans. Int. J. Biol. Macromol. 14 (1992) 225-228
28. Andersen P., and Doherty T.M. TB subunit vaccines - putting the pieces together. Microbes Infect. 7 (2005) 911-921
29. Mosmann T.R., and Sad S. The expanding universe of a T-cell subsets: Th1, Th2 and more. Immunol. Today 17 (1996) 138-146
30. Holten-Andersen L., Doherty T.M., Korsholm K.S., and Andersen P. Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines. Infect. Immun. 72 (2004) 1608-1617
31. Agnihotri S.A., Mallikarjuna N.N., and Aminabhavi T.M. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J. Control. Release 100 (2004) 5-28
32. R. Ylitalo, S. Lehtinen, E. Wuolijoki, P. Ylitalo, T. Lehtimäki, Cholesterol-lowering properties and safety of chitosan, 52 (2002) 1-7.
33. Leal I.S., Smedegard B., Andersen P., and Appelberg R. Interleukin-6 and interleukin-12 participate in induction of a type 1 protective T-cell response during vaccination with a tuberculosis subunit vaccine. Infect. Immun. 67 (1999) 5747-5754